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O B J E C T I V E S The purpose of the study was to understand determinants of infarct size in a primary
percutaneous intervention (PCI) population treated with pexelizumab compared with placebo.
B A C KG ROUND In the multicenter APEX-AMI (Pexelizumab in Conjunction With Angioplasty in
Acute Myocardial Infarction) trial, pexelizumab did not reduce 90-day mortality. Cardiac magnetic
resonance (CMR) with delayed enhancement was used in a substudy evaluating infarct size and left
ventricular ejection fraction (LVEF).
METHOD S Consecutive patients undergoing primary PCI for ﬁrst myocardial infarction (MI) as part
of the APEX-AMI trial were enrolled in this substudy at 5 centers. The CMR was completed on days 3 to
5 (n  99) and day 90 (n  83) following PCI. Central core lab-masked analyses for quantiﬁed LVEF,
volumes, and infarct size by planimetry were performed.
R E S U L T S Patients were 60 12 years of age, male (n 83 [84%]), had similar time from symptom onset
to presentation (median 2.6 h vs. 2.5 h; p  1.0), and similar baseline ST-segment deviation (13.5 mm vs. 14
mm; p  0.59) in both groups. Pexelizumab-treated patients had smaller infarct size (day 3 LV 10.5% vs.
16.2%, p  0.022; day 90 LV 5.9% vs. 12.4%, p  0.015) and higher LVEF (day 3 50.3% vs. 46.2%, p  0.073;
day 90 53.9% vs. 49.3%, p 0.036) compared with placebo-treated patients. Themedian peak creatine kinase
in the pexelizumab group was also signiﬁcantly less than placebo (922 mg/dl vs. 1,973 mg/dl; p  0.03).
Notably, the pexelizumab group had lower Thrombolysis In Myocardial Infarction (TIMI) ﬂow grade pre-PCI
(46.9% vs. 75.0%; p  0.018), a difference not seen in the overall APEX-AMI study. A multivariate model
including baseline features and pexelizumab treatment found anterior MI location and pre-PCI TIMI ﬂow to
be signiﬁcant independent predictors infarct size (p  0.001), whereas pexelizumab was not (p  0.29). No
death, heart failure, or shock was noted in either substudy group at 90 days.
CONC L U S I O N S In a CMR substudy of pexelizumab in MI, baseline TIMI ﬂow grade and anterior
location were the only predictors of infarct size, with a reduction of pre-PCI TIMI ﬂow grade 0 by 28%,
leading to a 35% reduction in infarct size. (The APEX-AMI Trial; NCT00091637) (J Am Coll Cardiol Img
2010;3:52–60) © 2010 by the American College of Cardiology Foundation
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53hen available, rapid primary percuta-
neous coronary intervention (PCI) is
the recommended therapy for patients
with acute ST-segment elevation myo-
ardial infarction (STEMI). Despite advances in
echnology and systems to decrease time from
resentation to reperfusion, patients continue to
uffer from significant morbidity and mortality fol-
owing STEMI. Myocardial ischemia and reperfu-
ion injury are felt to be important mechanisms
nderlying poor clinical outcomes (1). Pexelizumab is
n anti-C5 complement antibody that was shown in
nimal studies to reduce infarct size and improve
See page 61
entricular function in ischemia reperfusion models
2,3). In phase II clinical studies, pexelizumab,
hen given as a bolus plus infusion, was found to
educe mortality in patients with acute STEMI under-
oing percutaneous revascularization. This improvement
n mortality, however, was not associated with the ex-
ected reduction in infarct size as quantified by creatine
inase (CK)-myocardial band area under the curve up
o 72 h (4).
Cardiac magnetic resonance (CMR) allows for
igh-resolution assessment of infarct size, ven-
ricular volumes, and function as measured by
uantified ejection fraction (EF). The gadolin-
um delayed-enhancement cardiac magnetic res-
nance (DE-CMR) technique has been shown to
e sensitive for myocardial necrosis, allowing
isualization of minute amounts of necrosis/
carring as areas of hyperenhancement (5,6), and
ccurate for identification of both acute and
hronic infarction (7–10).
The APEX-AMI (Pexelizumab in Conjunc-
ion With Angioplasty in Acute Myocardial In-
arction) was a large multicenter clinical trial
valuating pexelizumab versus placebo in patients
ith acute ST-segment elevation undergoing pri-
ary percutaneous intervention (11). Given the
imitations of current blood biomarker estimates
f infarct size and the hypothesis that pexeli-
umab might improve myocardial healing as well
s reduce acute necrosis, we performed a CMR
ubstudy to determine if pexelizumab reduced
nfarct size and improved ventricular function.
o clinical benefit with pexelizumab treatment
as recently reported for the APEX-AMI study
11), and the results of the CMR substudy are
resented here. oE T H O D S
he APEX-AMI study design. The design and results
f the APEX-AMI study have been previously
ublished (12). Briefly, intravenous pexelizumab
as compared with placebo administered in a ran-
omized and blinded fashion immediately before
rimary PCI for electrocardiographically high-risk
TEMI patients within 6 hours of symptom onset.
atients were enrolled between July 13, 2004, and
ay 11, 2006, at 296 sites in 17 countries, with a
nal enrolled trial population of 5,745 patients. The
nstitutional review board at each participating hos-
ital approved the protocol, and patients were
equired to provide written informed consent.
MR substudy design. Consecutive patients enrolled
n the APEX-AMI trial at 5 international sites were
creened for inclusion in the CMR substudy. Patients
ith a prior history of MI, coronary artery
ypass surgery, or prior percutaneous inter-
ention were excluded because of potential
onfounding of infarct size measurement.
dditionally, patients with standard metallic
ontraindications to CMR were excluded.
side from study medication, patients were
reated according to standard of care by
nvestigators, including use of all concomi-
ant medications, procedural techniques,
nd use of adjunctive devices. Patients un-
erwent 2 dedicated CMR studies, 1 on day
to 5 and 1 on day 90 (1 week) following
ndex primary PCI (Fig. 1).
atient and procedural characteristics.
tandard baseline enrolled patient charac-
eristics such as age, cardiac risk factors,
ime from symptom onset to presentation,
nfarct location, and Killip class on presentation
ere collected. Detailed procedural findings includ-
ng time to PCI, culprit vessel, pre- and post-
hrombolysis In Myocardial Infarction (TIMI)
ow grade, and concomitant therapies were also
ollected. Coronary angiograms were evaluated at a
entral core angiographic laboratory (Cleveland
linic Angio Core Lab, Cleveland, Ohio). Admis-
ion electrocardiograms (ECGs) were also evalu-
ted at a core laboratory (Canadian VIGOUR
entre, Edmonton, Alberta, Canada; Duke Clini-
al Research Institute, Durham, North Carolina)
or degree of ST-segment deviation.
MR imaging. All images were acquired on 1.5-T
canners using a phased array coil during repeated
reath holds (8 to 10 s). The CMR exam consisted
A B B
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54mes and function and DE-CMR for infarct size
ssessment and evaluation of microvascular obstruc-
ion (MO). Briefly, cine- and DE-CMR images
ere obtained in matching short-axis planes (every
mm throughout the entire LV) and long-axis
lanes. Long-axis images were obtained in standard
-, 3-, and 4-chamber orientations. The cine-CMR
as performed using a steady-state free-precession
equence. Typical parameters were repetition time
f 3.0 ms, echo time of 1.5 ms; flip angle of 60°;
emporal resolution of 35 ms, in plane resolution of
.7  1.4 mm, slice thickness of 6 mm, and 2-mm
ap. The DE-CMR was performed using a seg-
ented inversion-recovery sequence (in-plane spa-
ial resolution 1.7  1.4 mm; temporal resolution
60 to 200 ms) 10 min after contrast administration
gadolinium 0.15 mmol/kg) (13,14). Inversion
imes were adjusted in the standard fashion to null
iable myocardium, typically 280 to 360 ms. Addi-
ionally, imaging was repeated after 10 min to
mprove detection and confirm areas of MO often
ermed “no reflow” (Fig. 2). Total time for the
MR evaluation was typically 30 to 40 min.
ENTRICULAR FUNCTION AND INFARCT SIZE
NALYSIS. All CMR images were analyzed in a
Figure 1. APEX-AMI CMR Substudy
(A) Diagram of cardiac magnetic resonance (CMR) study enrollment. (B) C
strates corresponding areas of infarction, seen as bright areas. LV  left ventral core lab (Duke Cardiovascular Magnetic Res- bnance Center, Durham, North Carolina). All core
ab assessments were performed without knowledge or
ccess to treatment assignment, procedural results, or
linical outcomes. Planimetry of myocardial borders
n all contiguous short-axis cine images, including pap-
llary muscles, was performed for left ventricular ejec-
ion fraction (LVEF) and ventricular volumes (Fig. 2).
he LVEF was calculated as follows: (volume at end
f diastole volume at end of systole)/(volume at end
f diastole). Similarly, LV mass was measured by plan-
metry of myocardial borders on all contiguous short-
xis DE-CMR images. Once the borders were identi-
ed, infarct size was quantified by planimetry of hy-
erenhanced areas on each short-axis image. Dark
reas within infarct regions representing MO were also
uantified by planimetry on the first DE-CMR im-
ges. Infarct size as a percentage of LV myocardium
as calculated by the sum of the volume of all hyperen-
anced regions on all slices divided by the sum of the
V myocardial cross-sectional volumes. Interobserver
nd intraobserver agreement for scar size in the CMR
ore laboratory using Bland-Altman analysis demon-
trated a bias of 1.0% and 0.1%, with a standard
eviation of differences of 2.6% and 0.8%, respectively.
tatistical analysis. For sample size determination, a
MR in long- and short-axis. Delayed enhancement CMR demon-
cular; MI  myocardial infarction; MRI  magnetic resonance imaging.ine-Caseline infarct size for the study population of 15% of
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55he left ventricle with a standard deviation 10% and
VEF of 45% with a standard deviation of 12% was
ssumed from recent primary percutaneous MI studies
15). Assuming that study patients with acute MI
ndergoing percutaneous revascularization would ob-
ain successful revascularization and myocardial im-
rovement demonstrated by a 33% decrease in infarct
ize and 10% increase in LVEF, a sample size of 85
atients was thought to provide 80% power to detect
significant relationship between pexelizumab ther-
py and improvement at an alpha level of 0.05.
ssuming approximately a 10% to 15% dropout rate
e.g., patients lost to follow-up, inability to return for
MR, death, interval implantation of ICD), we
nticipated that 100 enrolled patients would be
eeded to identify improvement in infarct size and/or
VEF with pexelizumab compared with placebo.
Baseline patient characteristics, procedural details,
nd CMR findings were described according to treat-
ent assignment to pexelizumab or placebo. Data for
ontinuous variables were presented in medians with
5th and 75th percentiles, and categoric variables were
resented as frequencies and percentages. Testing for
reatment differences was performed with Wilcoxon
ank sum tests for continuous variables, and chi-square
ests were used for categoric variables.
A general linear multivariate regression model was
Figure 2. Schematic of Cardiac Magnetic Resonance Imaging Ev
Planimetry of cine short-axis slices is performed during diastole and
delayed enhancement short-axis slices undergo planimetry for infar
enhancement imaging is demonstrated on the last row. Note, withi
regions) can be seen on initial delayed enhancement imaging (arro
areas) with time as seen on repeat delayed enhancement imaging.reated to assess the relationship between clinical eharacteristics and the infarct size on day 3 DE-
MR. Specifically, 3 modeling techniques were used:
) a model that begins with all the variables and then
emoves insignificant variables 1 at a time (backward);
) a model that begins with no variables and adds
ariables 1 at a time (forward); and 3) a model that
egins with all of the variables, then removes variables
at a time, and then assesses if an included variable
hould be removed (stepwise). All 3 modeling tech-
iques were used to see if there might be a difference
n results. Candidate variables chosen from baseline
nd procedural characteristics included age, MI loca-
ion, pre-PCI TIMI flow grade, hours from symptom
nset to randomization, qualifying Killip class, total
aseline ST-segment deviation, post-PCI TIMI flow
rade, and pexelizumab treatment. Normality as-
umptions were tested. The dependent variable was
ormally distributed. The predicted versus model
esiduals were plotted. There did not appear to be a
attern. A log transformation was used to model time
rom symptom onset to randomization, and a squared
erm was used to model total baseline ST-segment
eviation. All other continuous factors were modeled
inearly. Because the dependent variable for these
odels’ infarct size is continuous, significant predic-
ors from the model are presented by their predicted
tion
tole for ventricular volumes and function. The corresponding
ze. Microvascular obstruction imaging with repeat delayed
fracted regions, that the areas of microvascular obstruction (dark
These areas ﬁll in with contrast and hyperenhanced (bright
 left ventricular.alua
sys
ct si
n in
w).ffect on infarct size, with 95% confidence intervals.
A
(
R
D
s
s
w
m
i
o
T
a
p
q
p
d
f
P
o
t
i
a
A
t
s
t
t
s
A
(
s
o
w
w
t
N
1
p
b
0
0
t
P
i
2
t
c
0
p
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 3 , N O . 1 , 2 0 1 0
J A N U A R Y 2 0 1 0 : 5 2 – 6 0
Patel et al.
DE-CMR Substudy in the APEX-AMI Trial
56ll analyses were performed using SAS software
versions 8.2, SAS Institute, Cary, North Carolina).
E S U L T S
uring the APEX-AMI trial, 102 patients con-
ented to be in the CMR substudy at the time of
tudy enrollment. Of these 102 patients, 3 patients
ere excluded because of history of prior MI or
etallic contraindication to CMR after enrollment
n the trial. Therefore, 99 patients underwent CMR
n median day 3.0 (interquartile range 2.0 to 4.0).
wo patients completed cine-CMR but were un-
ble to undergo DE-CMR secondary to claustro-
hobia and difficulty with breath holds. Conse-
uently, infarct imaging was performed in 97
atients at baseline. After discharge, 16 patients
eclined follow-up DE-CMR, which was per-
ormed in 83 patients at median day 90 (Fig. 1).
atient characteristics. The baseline characteristics
f the entire APEX-AMI study population, of the
otal CMR substudy population, and by random-
zed treatment assignment in the CMR substudy
re presented in Table 1. Patients in the main
PEX-AMI study had ST-segment deviation pat-
erns similar to those of patients enrolled in the CMR
Table 1. Baseline Characteristics
Total APEX-A
(n  5,745
Median age, yrs (25th, 75th percentiles) 61 (52, 71
Female (%) 23.2
Median weight, kg (IQR) 80 (70–91
Clinical history (%)
Current smoker 43.4
Diabetes 16.0
Hypertension 49.5
Median creatinine clearance (IQR), ml/min 89 (80–10
Median heart rate, beats/min (IQR) 75 (65–86
Median systolic blood pressure, mm Hg (IQR) 133 (117–1
Killip class (%)
I 89.3
II 8.6
ECG core lab Infarct location, n (%)
High risk inferior 2,254 (40.8)
Median ST-segment deviation, mm (IQR) 13 (9–19)
Median ST-segment deviation, mm (IQR)
ECG core lab high-risk inferior 13.5 (9.5–18
ECG core lab anterior/lateral 12.5 (8.5–18
Median time from symptoms to enrollment, h (IQR) 2.8 (2–4)
There were no variables between the main APEX-AMI population and the CMR po
infarction was deﬁned by the presence at enrollment of 2-mm ST-segment
anterior leads for a total ST-segment deviation of 8 mm.
APEX-AMI  Pexelizumab in Conjunction With Angioplasty in Acute MyocardiaIQR  interquartile range.ubstudy, and patients in both groups had similar
imes from symptom onset to enrollment. Patients in
he CMR substudy tended to have Killip class I
ymptoms on presentation compared with the overall
PEX population, (95% vs. 89.4%; p  0.069).
In general, the patients in the 2 treatment groups
placebo vs. pexelizumab) of the CMR substudy had
imilar baseline characteristics. The median age of the
verall enrolled population was 60 years, and 16%
ere female. Time from symptom onset to enrollment
as similar between pexelizumab- and placebo-
reated patients (median 2.6 h vs. 2.5 h; p  1.0).
otably, systolic blood pressure (134.5 mm Hg vs.
40 mm Hg; p  0.73), Killip class I (92% vs. 98%;
 0.19), and the degree of ST-segment deviation on
aseline ECG (anterior 15 mm vs. 12.5 mm, p 
.19; high-risk inferior 13.3 mm vs. 15.8 mm, p 
.21) were similar between pexelizumab- and placebo-
reated patients.
rocedural characteristics. The procedural character-
stics by treatment assignment are presented in Table
. Once randomized, patients in both groups were
aken promptly, with slightly longer time to cardiac
atheterization, for revascularization (0.63 h vs.
.47 h; p  0.025) in pexelizumab- compared with
lacebo-treated patients. The infarct-related artery
Total CMR
(n  99)
Placebo
(n  49)
Pexelizumab
(n  50) p Value
60 (51, 70) 59 (51, 64) 61 (52, 73) 0.48
16.2 14.3 18 0.62
82 (72–94) 82 (71–92) 82.5 (73–97) 0.29
25.4 32.7 38 0.58
13.1 12.2 14.0 0.80
47.5 53.1 42.0 0.27
90 (80–106) 97.2 (80.0–106.1) 88.4 (79.6–97.2) 0.16
77 (66–85) 80 (68–85) 75 (65–80) 0.09
135 (120–150) 140 (120–155) 134.5 (122–147) 0.73
0.18
95 98 92
5 2 8
34 (34.7) 16 (32.7) 18 (36.0) 0.67
13.5 (10.5–17.0) 13.5 (10–17) 14.0 (11.3–18.0) 0.59
14.5 (12–18) 15.8 (12.3–20.8) 13.0 (12–17)
13.0 (10.5–17.0) 12.5 (9–17) 15 (10.0–19.5)
2.6 (2.0–3.3) 2.5 (2.0–3.3) 2.6 (1.8–3.2) 1.0
tion that reached statistical signiﬁcance (p 0.05). High-risk inferior myocardial
tion in 2 inferior leads coupled with ST-segment depression in 2 contiguous
rction; CMR  cardiac magnetic resonance imaging; ECG  electrocardiogram;MI
)
)
)
6)
)
50)
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57as similar between groups, with involvement of
he left anterior descending artery in 60% versus
1.9% (p  0.90) of pexelizumab- and placebo-
reated patients, respectively. Importantly, rates of
re-intervention TIMI flow grade 0 were signifi-
antly higher in placebo-treated patients compared
ith pexelizumab-treated patients (75% vs. 46.9%;
 0.005). Of note, this difference in pre-
ntervention TIMI flow grade 0 was not observed in
he overall APEX-AMI study: placebo (65.2%) and
exelizumab (63.5%). The TIMI flow grade 3
ost-intervention was high in both pexelizumab-
nd placebo-treated patients in the CMR substudy
92% vs. 85.7%; p  0.320). Core lab-measured
70% ST-segment resolution following percutane-
us revascularization was present in 58.7% of
exelizumab-treated patients compared with 40%
f placebo-treated patients (p  0.106).
MR ﬁndings. The main findings from the CMR
re presented in Table 3. On baseline CMR per-
ormed 3 to 5 days following STEMI, the median
nfarct size in the entire study group was 13.7% of
Table 2. Procedural Characteristics
Total APEX-A
(n  5,742
Median time from randomization to PCI, h (IQR) 0.50 (0.35–0.
TIMI ﬂow grade pre-intervention (%)
0 64.5
1 9.5
2 14.1
3 11.9
Infarct-related artery (%)
LAD 51.0
LCX 10.6
RCA 34.2
Median number of drug-eluting stents placed (IQR) 1 (1–2)
Median number of bare metal stents placed (IQR) 1 (1–1)
Any stent used (%) 95.5
Drug-eluting stent used (%) 41.5
Bare-metal stent used (%) 55.5
Use of glycoprotein IIb/IIIa (%) 71.6
TIMI ﬂow grade post-intervention (%)
0 2.5
1 0.9
2 6.6
3 90.0
ST-segment resolution post-intervention* (%)
30% 16.2
30%–70% 34.4
70% 49.5
There were no variables between the main APEX-AMI population and the CMR
LAD  left anterior descending; LCX  left circumﬂex; PCI  percutaneous cor
Infarction; other abbreviations as in Table 1.he LV. Pexelizumab treatment was associated with pignificant reduction in infarct size on baseline
MR (or median 10.5 vs. 16.2 % LV; p  0.022),
igher LVEF (50.3% vs. 46.2%; p  0.0376), and
trend of less MO (29.2% vs. 46.9%; p  0.072)
ompared with placebo-treated patients. Although
outine serial biomarker analysis was not mandated
uring the APEX-AMI study, investigators reported
hat peak CK levels were recorded. Pexelizumab-
reated patients had more than 50% lower reported
eak CK values (1,972 mg/dl vs. 922 mg/dl; p 0.03)
ompared with placebo-treated patients.
Follow-up CMR performed on day 90 also found
hat pexelizumab-treated patients had significantly
maller infarct size (median 5.9 vs. 12.4 % LV; p 
.015) compared with placebo-treated patients. Ad-
itionally at this time, pexelizumab-treated patients
ad significantly higher LVEF (53.9% vs. 49.3%; p
.026) compared with placebo-treated patients. It
hould be noted that differences in baseline findings
ikely accounted for differences at 90 days because the
hange in LVEF and infarct size between the 2 time
Total CMR
(n  99)
Placebo
(n  49)
Pexelizumab
(n  50) p Value
0.53 (0.33–0.75) 0.47 (0.33–0.63) 0.63 (0.33–0.93) 0.025
0.018
60.8 75.0 46.9
10.3 10.4 10.2
10.3 6.3 14.3
18.6 8.3 28.6
0.387
60.6 61.2 60.0
10.1 6.1 14.0
29.3 32.7 26.0
1 (1–1) 1 (1–1) 1 (1–1) 0.896
1 (1–2) 1 (1–2) 1 (1–2) 0.436
97.0 98.0 96.0 0.570
38.4 34.7 42.0 0.455
58.6 63.3 54.0 0.349
88.9 93.8 81.8 0.078
0.299
2.0 4.1 0
1.0 0 2.0
8.1 10.2 6.0
88.9 85.7 92.0
0.1061
15.4 22.2 8.7
35.2 37.8 32.6
49.5 40.0 58.7
lation that reached statistical signiﬁcance (p  0.05). *8 patients without data.
y intervention; RCA  right coronary artery; TIMI  Thrombolysis In MyocardialMI
)
71)
popu
onaroints was not significantly different between the
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58roups (Table 3). No clinical events (death, shock,
eart failure, or recurrent MI) were noted in any of the
MR substudy patients during a 6-month follow-up.
redictors of baseline infarct size. Candidate vari-
bles, including age, MI location, pre-PCI TIMI
ow grade, hours from symptom onset to enroll-
ent, qualifying Killip class, total baseline ST-
egment deviation, post-PCI TIMI flow, and
exelizumab treatment, were included in regression
odeling to determine predictors of baseline infarct
ize. Poor pre-PCI TIMI flow grade (0/1) and
nterior location of myocardial infarct were the only
ndependent predictors of baseline infarct size (p 
.0001). Pexelizumab treatment was not a predictor
Table 3. CMR and Biomarker Findings
Parameter Total
Day 3–5 CMR n 
Infarct size (% LV) (n  97) 13.7 (5
LVEF (%) 48.3 (3
LVEDV (ml) 130.3 (1
LVESV (ml) 64.6 (4
Microvascular obstruction on DE-CMR (%) (n  97) 3
Day 90 CMR n 
Infarct size (% LV) 8.8 (4
LVEF (%) 53.3 (4
LVEDV (ml) 124.5 (1
LVESV (ml) 58.5 (4
Change between day 90 and day 3–5 n 
LVEF (%) 3.7 (
LVEDV (ml) 3.7 (
LVESV (ml) 3.1 (
Infarct size (% LV) 3.5 (
Cardiac biomarker n 
Median peak CK (mg/dl) 1,559.5 (7
Values are 50th percentile (25th, 75th percentile) or %.
CK  creatine kinase; CMR  cardiac magnetic resonance; DE  delayed en
ejection fraction; LVESV  left ventricular end-systolic volume; MI  myocardia
Model for Baseline Infarct Size
able
Parameter
Estimate t Value p Value
0.02 0.24 0.81
nset to randomization 0.77 0.29 0.77
e 2 or 3 9.22 3.45 0.001
e 2 or 3 0.46 0.09 0.93
-segment deviation 0.12 0.16 0.87
ST-segment deviation 0.01 0.26 0.79
3.54 0.72 0.48
8.00 3.27 0.002
t 1.61 0.69 0.49
; PCI percutaneous coronary intervention; TIMI Thrombolysis In Myocardialif infarct size (p  0.29) (Table 4). The predicted
aseline infarct size based on pre-PCI TIMI flow
nd location of MI is presented in Table 5.
I S C U S S I O N
he principal finding from this substudy of the
PEX-AMI trial is smaller infarct size at baseline
nd at 90 days and related improved LVEF deter-
ined by CMR with pexelizumab treatment com-
ared with placebo among patients undergoing pri-
ary PCI for acute MI. Additionally, MO and
entricular volumes measured by CMR also trended
oward improvement in the pexelizumab group. In
ontrast, the overall APEX-AMI trial of 5,745 pa-
ients found no clinical effect on all-cause mortality or
eart failure in patients treated with pexelizumab
ompared with placebo at the time of primary PCI.
atients received rapid reperfusion with guideline-
ased care during the conduct of the trial, with an
verall observed 30-day mortality rate of only 4% (12).
The CMR substudy findings, in conjunction with
hose from angiographic and ECG data, do provide
n important perspective on reperfusion in acute MI
s reflected in infarct size and ventricular function.
everal studies have used radionuclide imaging for
nfarct size measurement in patients undergoing per-
utaneous intervention for acute MI. Recently, these
adionuclide studies reported the predictors of larger
ents Placebo Pexelizumab p Value
n  49 n  50
9.1) 16.2 (9.4, 20.2) 10.5 (4.7, 16.4) 0.022
55.6) 46.2 (37.1, 53) 50.3 (42.9, 57.5) 0.0376
, 156.7) 136.6 (110.3, 153) 119.3 (102.5, 156.7) 0.2273
83.5) 69.5 (55.4, 94.5) 58.3 (46.0, 81.7) 0.124
46.9 29.2 0.072
n  40 n  43
5.8) 12.4 (5.9, 16.9) 5.9 (2.2, 13.1) 0.015
59.1) 49.3 (39.6, 56.6) 53.9 (47, 61.8) 0.0259
, 158.6) 136.2 (112.2, 161.6) 117.1 (101.8, 151.2) 0.114
80.0) 66.2 (49.2, 92.5) 55.6 (41.4, 72.1) 0.046
n  40 n  43
, 7.2) 3.5 (1.3, 5.5) 4.7 (0.9, 7.5) 0.50
0, 16.9) 5.0 (6.9, 20.2) 3.3 (11.3, 14.8) 0.65
0, 7.4) 3.1 (12.4, 7.8) 3.1 (13.0, 6.5) 0.69
,1.5) 4.2 (8.8,4.2) 3.1 (4.8,1.4) 0.12
n 39 n  41
,811) 1,973 (895, 3,330) 922 (383, 2,304) 0.030
ement; LVEDV  left ventricular end-diastolic volume; LVEF  left ventricular
arction.Pati
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hancTable 4. Multivariate
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Time from symptom o
Pre-PCI TIMI ﬂow grad
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Linear term sum of ST
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Anterior MI
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59erfusion before and after angioplasty, male sex, time
o reperfusion, previous acute MI, and failed throm-
olysis (15). These studies are limited by variable
nclusion criteria (allowing prior thrombolysis in some
tudies) and variable time to infarct size imaging
anging from 5 to 35 days post-infarct.
The present study represents a select cohort of
atients in a large primary PCI acute MI study at
ultiple international sites undergoing primary
CI with robust assessment, including core lab-
uantified ECGs, angiograms, and CMR. Infarct
ize, MO, and ventricular function evaluation were
eadily imaged with standardized CMR techniques.
espite high-risk characteristics on ECG, delivery
f rapid effective reperfusion resulted in a small
edian infarct size that was only 13.7% of the LV
nd a median baseline LVEF that was 48.3% on
MR (Table 3). Even in this population, DE-
MR was able to detect modest but statistically
ignificant differences in infarct size (approximately
% LV) and LVEF (approximately 5%). The ob-
erved infarct size reduction was associated with a 28%
eduction in pre-PCI TIMI flow grade 0 and trends
oward improvement in post-PCI TIMI flow grade 3
nd post-PCI ST-segment resolution. Hence, this
tudy demonstrates that routine CMR examination in
atients with acute MI at baseline and follow-up is a
easible technique that allows for sensitive evaluation
f both infarct size and ventricular function. Addition-
lly, CMR helps in linking surrogate measures in the
hysiologic chain of events occurring during reperfu-
ion for acute MI from baseline ST-segment devia-
ion, pre-PCI TIMI flow grade, post-PCI TIMI
ow, ST-segment resolution, and baseline infarct size
n CMR to final 90-day LV function. The current
tudy confirms that anterior location and poor pre-
CI TIMI flow grade (0/1) are associated with larger
aseline infarct size.
There is discordance between the observed findings
rom the CMR substudy and the clinical findings
rom the APEX-AMI trial. There are 3 possible
xplanations: 1) pexelizumab may reduce infarct size,
n both this subset and the overall APEX-AMI trial,
ut had some counterbalancing effect that prevented
n overall clinical benefit; 2) CMR may have been
naccurate in assessing infarct size, and thus, it was
ncorrectly concluded that infarct size was reduced in
he substudy; or 3) given the selective bias inherent in
ubgroup analysis in a population of survivors, there
ay have been smaller infarcts in the pexelizumab
roup in the substudy population because of chance
ithout a similar effect in the overall trial.
We believe the third explanation is most likely.
ther results support the CMR findings of a smaller anfarct size. All available CMR measures performed
n both acute and chronic scans, including infarct size,
O, ventricular volumes, and LVEF, favor the
exelizumab-treated cohort. Although serial biomar-
er measurements were not mandated in the current
tudy, peak measured CK levels in this population also
ere significantly lower in the pexelizumab compared
ith placebo patients. Therefore, both internal and
xternal measures in the CMR substudy population
upport the CMR findings. However, data suggest
hat the CMR substudy population may have been
mbalanced, by chance, in favor of pexelizumab.
Specifically, the angiographic procedural findings
rovide insight into the observed differences in infarct
ize and subsequent ventricular function. Despite sim-
lar amounts of ST-segment deviation on baseline
CG and similar time from symptom onset to revas-
ularization, pexelizumab-treated patients had signif-
cantly lower rates of TIMI flow grade 0 on presen-
ation (46.9% vs. 75%; p  0.018) compared with
lacebo-treated patients. Because the pexelizumab
tudy drug was given only minutes before the angio-
ram and the drug was not expected to effect reperfusion
tself, this difference in baseline TIMI flow grade is likely
ue to chance. In fact, multivariable modeling including
exelizumab treatment found only anterior infarct loca-
ion and pre-PCI TIMI flow grade to be significant
redictors of infarct size. This difference in pre-PCI
IMI flow grade translated into post-procedural
IMI flow grade 3 rates and core lab ST-segment
esolution that also trended higher in pexelizumab-
reated patients compared with placebo-treated pa-
ients. Therefore, a difference in myocardial perfusion
ates as observed with pre-PCI TIMI flow grade rates
n angiogram may explain a difference in infarct size
nd subsequent ventricular function observed in the
MR substudy.
Notably, the CMR substudy patients represented
Table 5. Predictors of Baseline Infarct Size on CMR
Variable
% LV
Predicted Infarct Size 95%
High-risk inferior location
Pre-PCI TIMI ﬂow grade 2/3 5.74%
Pre-PCI TIMI ﬂow grade 0/1 12.70%
Anterior location
Pre-PCI TIMI ﬂow grade 0/1 20.93%
Pre-PCI TIMI ﬂow grade 2/3 9.92%
p value for the model is 0.0001. The independent predictors of baseline infa
location and TIMI ﬂow grade 0/1. These factors were attained using baselin
selection.
LV  left ventricular; other abbreviations as in Tables 1 and 2.Conﬁdence Interval
0.0%–13.68%
8.83%–16.58%
17.84%–24.02%
5.73%–14.10%
rct size were anterior MI
e, forward, and stepwiseselected population within the overall APEX-
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60MI study. Patients enrolled in the CMR study
id not have prior MI, and importantly, had to
urvive and be clinically stable to undergo CMR on
ays 3 to 5. This excluded patients with significant
ardiogenic shock and those requiring long-term
nvasive support. In contrast to the CMR substudy,
here was no difference in the observed pre-PCI
IMI flow grade or the peak reported CK levels in
he overall APEX-AMI trial. Therefore, although
e cannot exclude a treatment effect with pexeli-
umab in the CMR substudy, the findings likely
epresent a chance observation in a select popula-
ion not present in the overall study.
As with any biomarker or imaging measure,
MR with cine and DE cannot in isolation be used
o reliably determine effects on clinical outcomes.
lthough some initial data regarding clinical out-
omes are emerging (16), further research is re-
uired to understand the relationship between find-
ngs and clinical outcomes. Nevertheless, in thisof presence, location, and transmural
extent of healed Q-wave and non-Q- tion. Am Heart J 2hance, were found to have lower rates of “closed
rteries” with pre-PCI TIMI flow grade 0 at pre-
entation, leading to a small but statistically signif-
cant reduction in infarct size and improvement in
VEF as measured by CMR. These findings high-
ight the caution required in interpreting results
rom pilot and early phase studies and underscore
he importance of multiple measures of physiologic
nd clinical effect to understand treatments. CMR
s a robust and sensitive technique that provides
mportant mechanistic information on the effect of
herapies aimed at myocardial protection. Future
tudies on myocardial protection should consider
he use of CMR as part of a systematic approach
ncluding multiple measures of reperfusion to pro-
ide a comprehensive evaluation of effect.
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